select trial semaglutide cardiovascular outcomes non-diabetic 2023 SELECT Trial

Understanding the mechanism, risk factors, and management strategies can help patients make informed treatment decisions with their healthcare provider

Interaction was also observed between higher baseline HbA1C and more pronounced decrease in HbA1C

Explore second-phase GLP-1 study insights on improved medical cost growth, adherence and womens health.

Background In clinical trials enrolling patients with type 2 diabetes (T2D) at high cardiovascular risk, many glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improved albuminuria status and possibly mitigated kidney function loss

Explore how nutrition can support natural GLP-1 production, a hormone key to blood sugar regulation and weight management, often targeted by popular weight loss medications

Stopping Ozempic isnt just about ending a medication